WaveMan
WaveMan · Company
SYRE · Spyre Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

SYRE Spyre Therapeutics (SYRE) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001636282
Quote by TradingView
Form 144 · 7
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
192
13F, latest reported quarter
Conversions, 180 days
16
Codes C/M, not in net · $4.7M priced

What the filings say about SYRE

Insiders, 180 days
-$438.3M net sold
7 sellers · 40% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$17.7M
7 notices

Spyre Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Spyre Therapeutics, Inc. insiders sold a net $438.3M of stock across 100 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Burrows Scott L
Chief Financial Officer
SELL
2026-10-02 SECtraded 2026-10-01
600
$53.4K
+0.2%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Sep 30, 2026.
  • The trade is 0.7% of the 86,662 shares held after it.
  • 2 other insiders sold within 30 days.
  • 192 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Burrows Scott L sold about $53.4K of SYRE under a 10b5-1 plan on Oct 1, 2026; 2 other insiders sold within 30 days and 192 funds added in the latest 13F quarter.
Burrows Scott L
Chief Financial Officer
SELL
2026-10-02 SECtraded 2026-10-01
1,500
$135.4K
+0.2%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Sep 30, 2026.
  • The trade is 1.8% of the 85,162 shares held after it.
  • 2 other insiders sold within 30 days.
  • 192 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Burrows Scott L sold about $135.4K of SYRE under a 10b5-1 plan on Oct 1, 2026; 2 other insiders sold within 30 days and 192 funds added in the latest 13F quarter.
Burrows Scott L
Chief Financial Officer
SELL
2026-10-02 SECtraded 2026-10-01
2,100
$193.0K
+0.2%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Sep 30, 2026.
  • The trade is 2.5% of the 83,062 shares held after it.
  • 2 other insiders sold within 30 days.
  • 192 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Burrows Scott L sold about $193.0K of SYRE under a 10b5-1 plan on Oct 1, 2026; 2 other insiders sold within 30 days and 192 funds added in the latest 13F quarter.
Burrows Scott L
Chief Financial Officer
SELL
2026-10-02 SECtraded 2026-10-01
3,071
$285.4K
+0.2%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Sep 30, 2026.
  • The trade is 3.8% of the 79,991 shares held after it.
  • 2 other insiders sold within 30 days.
  • 192 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Burrows Scott L sold about $285.4K of SYRE under a 10b5-1 plan on Oct 1, 2026; 2 other insiders sold within 30 days and 192 funds added in the latest 13F quarter.
Burrows Scott L
Chief Financial Officer
SELL
2026-10-02 SECtraded 2026-10-01
229
$21.4K
+0.2%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Sep 30, 2026.
  • The trade is 0.3% of the 79,762 shares held after it.
  • 2 other insiders sold within 30 days.
  • 192 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Burrows Scott L sold about $21.4K of SYRE under a 10b5-1 plan on Oct 1, 2026; 2 other insiders sold within 30 days and 192 funds added in the latest 13F quarter.
100 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 95 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$438.3M over 180 days
-$16.9M over 90 days
the lowest in Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
192 funds bought in last quarter
more than 89% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
15.6% of the float short (float per yahoo 2026-10-26) · 8.9 days to cover · settled 2026-09-30
more than 84% of Pharma & Biotech
What changed in the last 30 days
Oct 2See Remarks King-Jones Heidy sold $2.6M under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 2Chief Financial Officer Burrows Scott L sold $2.3M under a 10b5-1 plan (6 trades, Sep 30 to Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 1Director CAMERON TURTLE filed to sell $4.0M by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 1Officer HEIDY KING-JONES filed to sell $2.6M by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Sep 30Officer SCOTT BURROWS filed to sell $1.6M by Sep 30 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch SYRE

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+318.3%12M
-0%+130%+260%+390%2025-102025-122026-022026-042026-062026-082026-10 2026-06-23 · Fairmount Funds Management LLC sold $399.7M2026-05-08 · HENDERSON MICHAEL THOMAS sold $2.5M2026-06-22 · HENDERSON MICHAEL THOMAS sold $2.0M2026-05-08 · HENDERSON MICHAEL THOMAS sold $1.9M2026-09-02 · Burrows Scott L sold $1.6M2026-09-30 · Burrows Scott L sold $1.6M2026-10-01 · King-Jones Heidy sold $1.5M2026-05-01 · Sloan Sheldon sold $1.5M2026-05-08 · HENDERSON MICHAEL THOMAS sold $1.5M2026-09-01 · King-Jones Heidy sold $1.4M2026-05-01 · Sloan Sheldon sold $1.4M2026-08-07 · Albers Jeffrey W. sold $1.0M2026-05-01 · Sloan Sheldon sold $932.0K2026-05-01 · Burrows Scott L sold $892.1K2026-07-01 · Turtle Cameron sold $889.8K2026-06-25 · Burrows Scott L sold $871.4K2026-08-07 · Albers Jeffrey W. sold $835.0K2026-05-01 · Sloan Sheldon sold $763.8K2026-09-01 · Turtle Cameron sold $732.1K2026-08-03 · Turtle Cameron sold $680.6K2026-10-01 · King-Jones Heidy sold $660.3K2025-11-03 · Turtle Cameron sold $651.2K2026-05-01 · Sloan Sheldon sold $628.1K2026-06-03 · Sloan Sheldon sold $625.0K2026-04-01 · Turtle Cameron sold $607.3K2026-06-01 · Turtle Cameron sold $574.5K2026-07-01 · Sloan Sheldon sold $568.9K2026-09-01 · King-Jones Heidy sold $547.2K2026-08-03 · Turtle Cameron sold $540.6K2026-08-07 · Albers Jeffrey W. sold $522.4K2026-07-01 · Burrows Scott L sold $505.6K2026-08-03 · Burrows Scott L sold $485.6K2026-10-01 · Turtle Cameron sold $465.9K2026-02-02 · Turtle Cameron sold $461.6K2026-06-25 · Burrows Scott L sold $435.6K2026-09-01 · King-Jones Heidy sold $418.6K2025-11-03 · Turtle Cameron sold $398.6K2026-04-01 · Sloan Sheldon sold $397.9K2026-01-02 · Turtle Cameron sold $387.2K2026-03-02 · Turtle Cameron sold $386.7K2026-09-01 · Burrows Scott L sold $381.9K2026-05-01 · Sloan Sheldon sold $377.4K2026-10-01 · HEIDY KING-JONES filed to sell $2.6M2026-10-01 · CAMERON TURTLE filed to sell $4.0M2026-09-30 · SCOTT BURROWS filed to sell $1.6M2026-09-01 · HEIDY KING-JONES filed to sell $4.2M2026-08-07 · SESSIONS, LLC filed to sell $1.9M2026-08-07 · JEFFREY ALBERS filed to sell $517.1K2026-08-03 · SCOTT BURROWS filed to sell $2.9M2026-07-01 · CAMERON TURTLE filed to sell $4.0M2026-06-25 · SCOTT BURROWS filed to sell $1.3M2026-06-23 · Fairmount Healthcare Fund II L.P. filed to sell $399.7M2026-06-22 · MICHAEL HENDERSON filed to sell $1.8M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SYRE: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
13,026,187 sh
$1.2B
BlackRock, Inc.
6,506,605 sh
$577.7M
PERCEPTIVE ADVISORS LLC
4,319,496 sh
$383.5M
RTW INVESTMENTS, LP
4,251,996 sh
$377.5M
Paradigm Biocapital Advisors LP
3,840,778 sh
$341.0M

Congress trades in SYRE

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SYRE planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
HEIDY KING-JONES
Filed 2026-10-01
$2.6M
CAMERON TURTLE
Filed 2026-10-01
$4.0M
SCOTT BURROWS
Filed 2026-09-30
$1.6M
HEIDY KING-JONES
Filed 2026-09-01
$4.2M
SESSIONS, LLC
Filed 2026-08-07
$1.9M

SYRE mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
F/m Emerald Life Sciences Innovation ETF
$6.7M position · as of 2026-05-31
6.4%
Fidelity Advisor Biotechnology Fund
$84.3M position · as of 2026-07-31
3.8%
ALPS Medical Breakthroughs ETF
$6.0M position · as of 2026-05-31
3.7%
Invesco Dorsey Wright Healthcare Momentum ETF
$4.7M position · as of 2026-07-31
2.0%
Driehaus Micro Cap Growth Fund
$11.9M position · as of 2026-06-30
2.0%
Franklin Biotechnology Discovery Fund
$21.6M position · as of 2026-07-31
1.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
8 registered trials, 5 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
4
Phase 1
1 active
4
Phase 2
4 active
What changed recently
A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIG
2026-10-20 · Not Yet Recruiting → Recruiting
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Dr.Anthony Quinn
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2021
$2.6M
$361.5K
$1.4M
-40%
+0%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $438.3M sold by insiders over 180 days, 192 funds added last quarter, $17.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

SYRE financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2024-01-01 to 2024-12-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-23.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-20.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-25.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$0$0$886.0K$2.3M
Operating income-$209.6M-$208.6M-$242.3M-$84.8M
Net income-$155.2M-$208.0M-$338.8M-$83.8M
EPS (diluted)n/an/a13.76-24.86
Operating cash flow-$169.3M-$157.4M-$99.9M-$80.1M
Cash$85.7M$89.4M$188.9M$34.9M
SEC XBRL, fiscal years, as known on 2026-10-27

SYRE Stock Sonar score 4/7 axes

Find similar shapesCompare

SYRE ranks highest on profitability (69th percentile) and institutional and government (51st), and lowest on insider conviction (1st), among Pharma & Biotech peers.

Profitability
69
Inputs
  • Return on equity-23.0% · 70 pct, sector of 545
  • Return on assets-20.9% · 66 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-25.7% · 70 pct, sector of 576
Insider conviction
0
Inputs
  • Net Form 4 buying (codes P and S), 180d-$426.0M · 0 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
51
Inputs
  • Funds adding, latest quarter192 · 89 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$60K · 12 pct, sector of 133
Risk and compliance
17
Inputs
  • Short interest, % of float+15.6% · 24 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+26.5% · 10 pct, sector of 511
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

SYRE filings, in plain words

Are Spyre Therapeutics insiders buying or selling SYRE?

In the 180 days to 2026-10-27, Spyre Therapeutics insiders were net sellers, a net $438.3M across purchases and sales reported on Form 4, by 7 sellers.

Are there planned insider sales of SYRE?

Yes. 7 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $17.7M of stock; the latest, by HEIDY KING-JONES, was filed 2026-10-01.

Read the full summary

In the 180 days to 2026-10-27, Spyre Therapeutics insiders were net sellers of SYRE, a net $438.3M across purchases and sales reported on Form 4 by 7 sellers. 40% of the 78 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 7 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $17.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies